{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:24:35Z","timestamp":1793831075995,"version":"4.6.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2023.101092","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T16:34:40Z","timestamp":1682008480000},"page":"101092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Does PTCY increase the risk of infections?"],"prefix":"10.1016","volume":"62","author":[{"given":"Malgorzata","family":"Mikulska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bartalucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Raiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Oltolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101092_bb0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fimmu.2020.00191","article-title":"Key aspects of the Immunobiology of Haploidentical hematopoietic cell transplantation","volume":"11","author":"Baumeister","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.blre.2023.101092_bb0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s15010-017-1016-1","article-title":"A review of infectious complications after haploidentical hematopoietic stem cell transplantations","volume":"45","author":"Atilla","year":"2017","journal-title":"Infection"},{"issue":"10","key":"10.1016\/j.blre.2023.101092_bb0015","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41409-019-0475-7","volume":"54","author":"Fayard","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101092_bb0020","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41409-021-01328-4","article-title":"Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide","volume":"56","author":"Esquirol","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101092_bb0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41409-020-01092-x","article-title":"Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching","volume":"56","author":"Irene","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2023.101092_bb0030","first-page":"395","article-title":"Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.blre.2023.101092_bb0035","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.bbmt.2020.01.013","article-title":"Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA matching","volume":"26","author":"Oltolini","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101092_bb0040","first-page":"695","article-title":"Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.blre.2023.101092_bb0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-020-00923-0","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors","volume":"13","author":"Brissot","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101092_bb0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"Battipaglia","year":"2020","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.blre.2023.101092_bb0055","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs. antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101092_bb0060","series-title":"2022 ASH Annual Meeting and Exposition. Abstract LBA-4. Presented December 13","article-title":"Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease prophylaxis in reduced intensity conditioning: Results from phase III BMT CTN 1703","author":"Holtan","year":"2022"},{"key":"10.1016\/j.blre.2023.101092_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732826","article-title":"CMV infection and CMV-specific immune reconstitution following Haploidentical stem cell transplantation: an update","volume":"12","author":"Luo","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2023.101092_bb0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JBM.S201073","article-title":"Increased risk of 100-day and 1-year infection-related mortality and complications in haploidentical stem cell transplantation","volume":"10","author":"Chang","year":"2019","journal-title":"J Blood Med"},{"issue":"23","key":"10.1016\/j.blre.2023.101092_bb0075","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101092_bb0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.17563","article-title":"Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation","volume":"194","author":"Mulroney","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101092_bb0085","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbmt.2018.07.008","article-title":"Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in Haploidentical hematopoietic stem cell transplants for hematological malignancies","volume":"24","author":"Law","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101092_bb0090","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13096","article-title":"Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.blre.2023.101092_bb0095","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/bjh.16189","article-title":"Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation","volume":"187","author":"Mohty","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101092_bb0100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/jha2.20","article-title":"Progressive substitution of posttransplant cyclophosphamide with bendamustine: a phase I study in haploidentical bone marrow transplantation","volume":"1","author":"Katsanis","year":"2020","journal-title":"EJHaem"},{"issue":"8","key":"10.1016\/j.blre.2023.101092_bb0105","first-page":"510.e511","article-title":"Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.blre.2023.101092_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac687","article-title":"Real-world outcomes associated with Letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies","volume":"10","author":"Vyas","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.blre.2023.101092_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041106","article-title":"Addition of a single low dose of anti T-lymphocyte globulin to post-transplant cyclophosphamide after allogeneic hematopoietic stem cell transplant: a pilot study","volume":"11","author":"Xue","year":"2022","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101092_bb0120","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021006213","article-title":"Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation","volume":"6","author":"Lorentino","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2023.101092_bb0125","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41409-017-0016-1","article-title":"Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haploHSCT with PT-cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT","volume":"53","author":"Cesaro","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2023.101092_bb0130","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.3324\/haematol.2016.149880","article-title":"Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide","volume":"101","author":"Goldsmith","year":"2016","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.blre.2023.101092_bb0135","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1080\/10428194.2020.1797010","article-title":"High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis","volume":"61","author":"Salas","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2023.101092_bb0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.hemonc.2018.11.002","article-title":"Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide","volume":"12","author":"Mohyuddin","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"10.1016\/j.blre.2023.101092_bb0145","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13626","article-title":"Clinical impact of multiple DNA virus infections in nondepleted haploidentical and unrelated allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Kerbauy","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.blre.2023.101092_bb0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jcv.2016.07.002","article-title":"Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Hubmann","year":"2016","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.blre.2023.101092_bb0155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbmt.2017.08.024","article-title":"Pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation: impact of T cell-replete transplantation from a Haploidentical donor","volume":"24","author":"Mikulska","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2023.101092_bb0160","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/cid\/cix690","article-title":"Incidence, risk factors and outcome of pre-engraftment gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey","volume":"65","author":"Girmenia","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.blre.2023.101092_bb0165","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13611","article-title":"Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: analysis of the China assessment of antifungal therapy in hematological diseases (CAESAR) study","volume":"23","author":"Sun","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"12","key":"10.1016\/j.blre.2023.101092_bb0170","first-page":"850","article-title":"Bacterial bloodstream infections in patients undergoing allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Salas","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2023.101092_bb0175","article-title":"Levofloxacin prophylaxis vs. no prophylaxis in neutropenic patients within an endemic country for carbapenem-resistant GNB","author":"Clerici","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101092_bb0180","article-title":"The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study","author":"Ramanathan","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101092_bb0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infect"},{"issue":"7","key":"10.1016\/j.blre.2023.101092_bb0190","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/ciab404","article-title":"Colonization with fluoroquinolone-resistant Enterobacterales decreases the effectiveness of fluoroquinolone prophylaxis in hematopoietic cell transplant recipients","volume":"73","author":"Satlin","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.blre.2023.101092_bb0195","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/cid\/cix646","article-title":"Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the infectious diseases working party of the European bone marrow transplantation group","volume":"65","author":"Averbuch","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.blre.2023.101092_bb0200","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jinf.2020.11.002","article-title":"Intercontinental study on pre-engraftment and post-engraftment gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: risk factors and association with mortality","volume":"81","author":"Averbuch","year":"2020","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.blre.2023.101092_bb0205","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/cid\/ciz319","article-title":"Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance","volume":"70","author":"Martinez-Nadal","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.blre.2023.101092_bb0210","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01744-21","article-title":"Impact of empirical antibiotic regimens on mortality in neutropenic patients with bloodstream infection presenting with septic shock","volume":"66","author":"Chumbita","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.blre.2023.101092_bb0215","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2023.101092_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12629","article-title":"Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation","volume":"19","author":"Slade","year":"2017","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.blre.2023.101092_bb0225","article-title":"Comparison of three distinct prophylactic agents against invasive fungal infections in patients undergoing Haplo-identical hematopoietic stem cell transplantation and post-transplant cyclophosphamide","volume":"7","author":"El-Cheikh","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"8","key":"10.1016\/j.blre.2023.101092_bb0230","first-page":"508.e501","article-title":"Invasive yeast infection after Haploidentical donor hematopoietic cell transplantation associated with cytokine release syndrome","volume":"28","author":"Little","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.blre.2023.101092_bb0235","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41409-019-0459-7","article-title":"Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed\/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT","volume":"54","author":"Battipaglia","year":"2019","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2300053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2300053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:57Z","timestamp":1759437117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X2300053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":47,"alternative-id":["S0268960X2300053X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101092","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does PTCY increase the risk of infections?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101092"}}